Vaccination and infection prevention in inflammatory bowel disease

F1000 Medicine Reports

Volumn 2, Issue 1, 2010, Pages

  Vermeire, Severine ^a   Van Assche, Gert ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ANTIVIRUS AGENT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CHICKENPOX VACCINE; CORTICOSTEROID; GAMMA INTERFERON; HEPATITIS B VACCINE; IMMUNOMODULATING AGENT; INFLIXIMAB; INFLUENZA VACCINE; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NUCLEOSIDE ANALOG; PNEUMOCOCCUS VACCINE; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

CHICKENPOX; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; CONSENSUS DEVELOPMENT; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE SEVERITY; DRUG SAFETY; ENTERITIS; EUROPE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; IMMUNOMODULATION; INFECTION; INFECTION RISK; INFLUENZA; LIVER DYSFUNCTION; LIVER FAILURE; MAJOR CLINICAL STUDY; MORTALITY; OPPORTUNISTIC INFECTION; PNEUMOCOCCAL INFECTION; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; SEROLOGY; SHORT SURVEY; SKIN TEST; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; ULCERATIVE COLITIS; VACCINATION; VIRUS INFECTION; YELLOW FEVER;

EID: 78649366906     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M2-80     Document Type: Short Survey

References (9)

1. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-36. F1000 Factor 9 Evaluated by Paul Pavli 22 Apr 2008, Klaus Monkemuller 13 Jan 2009
2. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, Domènech E, Eliakim R, Eser A, Frater J, Gassull M, Giladi M, Kaser A, Lémann M, Moreels T, Moschen A, Pollok R, Reinisch W, Schunter M, Stange EF, Tilg H, Van Assche G, Viget N, Vucelic B, Walsh A, Weiss G, Yazdanpanah Y, Zabana Y, Travis SPL, Colombel JF; European Crohn's and Colitis Organisation (ECCO): European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2009, 3:47-91.
3. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, Van Assche G, Vermeire S, Rutgeerts P: Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-8.
4. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B: Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009, 30:253-64.
5. Rahier JF, Yazdanpanah Y, Colombel JF, Travis S: The European (ECCO) Consensus on infection in IBD: what does it change for the clinician? Gut 2009, 58:1313-5.
6. Loras C, Saro C, Gonzalez-Huix F, Mínguez M, Merino O, Gisbert JP, Barrio J, Bernal A, Gutiérrez A, Piqueras M, Calvet X, Andreu M, Abad A, Ginard D, Bujanda L, Panés J, Torres M, Fernández-Bañares F, Viver JM, Esteve M; GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa): Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009, 104:57-63.
7. Chevaux JB, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, Gueant JL, Bigard MA, Bronowicki JP, Peyrin-Biroulet L: Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis 2010, 16:916-24.
8. Loras C, Gisbert JP, Mínguez M, Merino O, Bujanda L, Saro C, Domenech E, Barrio J, Andreu M, Ordás I, Vida L, Bastida G, González-Huix F, Piqueras M, Ginard D, Calvet X, Gutiérrez A, Abad A, Torres M, Panés J, Chaparro M, Pascual I, Rodriguez-Carballeira M, Fernández-Bañares F, Viver JM, Esteve M; REPENTINA study; GETECCU (Grupo Español de Enfermedades de Crohn y Colitis Ulcerosa) Group: Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010, 59:1340-6.
9. Seksik P, Cosnes J, Sokol H, Nion-Larmurier I, Gendre JP, Beaugerie L: Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine. Aliment Pharmacol Ther 2009, 29:1106-13.